Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2022-03-07 02:48:59 UTC |
---|
HMDB ID | HMDB0000053 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Androstenedione |
---|
Description | Androstenedione is a delta-4 19-carbon steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol. It is the common precursor of male and female sex hormones. Some androstenedione is also secreted into the plasma and may be converted in peripheral tissues to testosterone and estrogens. Androstenedione originates either from the conversion of dehydroepiandrosterone or from 17-hydroxyprogesterone. It is further converted to either testosterone or estrone. The production of adrenal androstenedione is governed by ACTH, while the production of gonadal androstenedione is under control by gonadotropins. |
---|
Structure | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1 |
---|
Synonyms | Value | Source |
---|
4-Androstene-3,17-dione | ChEBI | 4-ANDROSTENE-3-17-dione | ChEBI | delta(4)-Androsten-3,17-dione | ChEBI | delta(4)-Androstene-3,17-dione | ChEBI | Δ(4)-Androsten-3,17-dione | Generator | Δ(4)-Androstene-3,17-dione | Generator | (4)-Androsten-3,17-dione | HMDB | 17-Ketotestosterone | HMDB | 3,17-Dioxoandrost-4-ene | HMDB | 4-Androsten-3,17-dione | HMDB | 4-Androstenedione | HMDB | Androst-4-ene-3,17-dione | HMDB, KEGG | Androstendione | HMDB | D4-Androstene-3,17-dione | HMDB | delta4-Androstenedione | HMDB | Fecundin | HMDB | delta 4 Androstenedione | MeSH, HMDB | delta-4-Androstenedione | MeSH, HMDB | 4 Androstene 3,17 dione | MeSH, HMDB | Androstenedione | HMDB | delta4-Androstene-3,17-dione | HMDB | Δ4-Androstene-3,17-dione | HMDB |
|
---|
Chemical Formula | C19H26O2 |
---|
Average Molecular Weight | 286.4085 |
---|
Monoisotopic Molecular Weight | 286.193280076 |
---|
IUPAC Name | (1S,2R,10R,11S,15S)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,14-dione |
---|
Traditional Name | (1S,2R,10R,11S,15S)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,14-dione |
---|
CAS Registry Number | 63-05-8 |
---|
SMILES | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1 |
---|
InChI Key | AEMFNILZOJDQLW-QAGGRKNESA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- Oxosteroid
- 17-oxosteroid
- 3-oxosteroid
- 3-oxo-delta-4-steroid
- Delta-4-steroid
- Cyclohexenone
- Cyclic ketone
- Ketone
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 170 - 173 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.058 mg/mL | Not Available | LogP | 2.75 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Androstenedione,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2739.9 | Semi standard non polar | 33892256 | Androstenedione,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2460.2 | Standard non polar | 33892256 | Androstenedione,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2902.2 | Standard polar | 33892256 | Androstenedione,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CCC2=O | 2630.6 | Semi standard non polar | 33892256 | Androstenedione,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CCC2=O | 2564.3 | Standard non polar | 33892256 | Androstenedione,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CCC2=O | 2995.0 | Standard polar | 33892256 | Androstenedione,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2694.2 | Semi standard non polar | 33892256 | Androstenedione,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2621.7 | Standard non polar | 33892256 | Androstenedione,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2963.6 | Standard polar | 33892256 | Androstenedione,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C | 2978.8 | Semi standard non polar | 33892256 | Androstenedione,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C | 2622.0 | Standard non polar | 33892256 | Androstenedione,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C | 3066.2 | Standard polar | 33892256 | Androstenedione,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CCC(=O)[C@@]3(C)CC[C@@H]12 | 2874.7 | Semi standard non polar | 33892256 | Androstenedione,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CCC(=O)[C@@]3(C)CC[C@@H]12 | 2806.7 | Standard non polar | 33892256 | Androstenedione,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CCC(=O)[C@@]3(C)CC[C@@H]12 | 3159.2 | Standard polar | 33892256 | Androstenedione,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CC=C(O[Si](C)(C)C(C)(C)C)[C@@]3(C)CC[C@@H]12 | 3215.9 | Semi standard non polar | 33892256 | Androstenedione,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CC=C(O[Si](C)(C)C(C)(C)C)[C@@]3(C)CC[C@@H]12 | 2932.7 | Standard non polar | 33892256 | Androstenedione,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C)C(=C1)CC[C@H]1[C@@H]3CC=C(O[Si](C)(C)C(C)(C)C)[C@@]3(C)CC[C@@H]12 | 3219.2 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Androstenedione GC-MS (Non-derivatized) | splash10-004l-5910000000-518e1ad38bcc73325b53 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Androstenedione GC-MS (Non-derivatized) | splash10-004l-5910000000-5172e05f9889ee2bfaf4 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Androstenedione EI-B (Non-derivatized) | splash10-000f-8940000000-f2892fe3b281d44164c8 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Androstenedione EI-B (Non-derivatized) | splash10-007d-1960000000-167f1765b095da9d603b | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Androstenedione GC-MS (Non-derivatized) | splash10-004l-5910000000-518e1ad38bcc73325b53 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Androstenedione GC-MS (Non-derivatized) | splash10-004l-5910000000-5172e05f9889ee2bfaf4 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Androstenedione GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-0590000000-502d6b821317a01a1990 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Androstenedione GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-059m-3940000000-9cb32ac21e46afb2829a | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-000i-0090000000-36e848ba16b141eef47b | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-052b-9600000000-712954fc35a84c8217de | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-052b-9300000000-f8e9aa16b4b208b69f7b | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione EI-B (HITACHI M-80) , Positive-QTOF | splash10-000f-8940000000-e12025ea2b7808c64b9c | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione LC-ESI-ITFT , positive-QTOF | splash10-052b-6910000000-b616785c86a92f46158e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione LC-ESI-ITFT , positive-QTOF | splash10-052b-9800000000-73e545a1eb2232d55371 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione LC-ESI-ITFT , positive-QTOF | splash10-00kb-5790000000-735473bc44dd70e29259 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione LC-ESI-ITFT , positive-QTOF | splash10-00kb-5790000000-114675a4457063901f2b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 55V, Positive-QTOF | splash10-052b-7910000000-f0d8591998137c42f717 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 35V, Positive-QTOF | splash10-00kb-5790000000-f47366cff1ef47253455 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 80V, Positive-QTOF | splash10-052b-9800000000-58ced8830fbdd255377e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 55V, Positive-QTOF | splash10-00kb-5790000000-4d32bf4d34aaef92de91 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 60V, Positive-QTOF | splash10-052b-9700000000-5a645018a15e2dd1adeb | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 75V, Positive-QTOF | splash10-052b-9500000000-70913f3a4e21abdcf9ee | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 75V, Positive-QTOF | splash10-052b-9500000000-1405c9c7f6ea07c8d1e4 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 20V, Positive-QTOF | splash10-000i-0090000000-eec15e6fd9d08b27ef07 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 10V, Positive-QTOF | splash10-000i-0090000000-778071650dcadc3b3069 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 50V, Positive-QTOF | splash10-00c3-0900000000-faf22b1b9717d889edd8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Androstenedione 30V, Positive-QTOF | splash10-00ei-0940000000-930c091a3d1471221653 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Androstenedione 10V, Positive-QTOF | splash10-000i-0190000000-0347db9e9578e8d5d6f2 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Androstenedione 20V, Positive-QTOF | splash10-05pc-0490000000-d4049441f1c172450dc3 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Androstenedione 40V, Positive-QTOF | splash10-0uk9-4790000000-355bc0834a6465ecad30 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Androstenedione 10V, Negative-QTOF | splash10-000i-0090000000-887b6f223b77c683ef99 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Androstenedione 20V, Negative-QTOF | splash10-000i-0090000000-9dafdd780cca012f1fb3 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Androstenedione 40V, Negative-QTOF | splash10-05mo-2190000000-264074b1eefeed0e3103 | 2017-07-26 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, CDCl3, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | 2012-12-04 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
- Endoplasmic reticulum
|
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Urine
|
---|
Tissue Locations | - Adipose Tissue
- Adrenal Cortex
- Adrenal Gland
- Epidermis
- Fibroblasts
- Kidney
- Liver
- Ovary
- Placenta
- Prostate
- Skeletal Muscle
- Testis
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.000698 uM | Newborn (0-30 days old) | Female | Normal | | details | Blood | Detected and Quantified | 0.00244-0.00768 uM | Not Specified | Not Specified | Normal | | details | Blood | Detected and Quantified | <0.0140 uM | Infant (0-1 year old) | Not Specified | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.00489 +/- 0.00196 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0059 (0.0023-0.0094) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.00315 (0.00000-0.00630) uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.00524 +/- 0.00140 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.000978-0.00803 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.00061 +/- 0.00022 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | <0.00100 uM | Not Specified | Both | Normal | | details | Blood | Detected and Quantified | 0.0022 (0.0010-0.0034) uM | Children (1-13 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.005 (0.0024-0.0070) uM | Adolescent (13-18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0040 (0.0013-0.0066) uM | Children (1-13 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.001 (0.00034-0.00170) uM | Children (1-13 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0057 (0.00069-0.01) uM | Adult (>18 years old) | Female | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00101 (0.00002-0.002) uM | Adult (>18 years old) | Not Specified | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Normal | | details | Urine | Detected and Quantified | 0.00009 (0.00003-0.00077) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 0.0007 (0-0.0052) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 0.090 +/- 0.058 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.0068 +/- 0.0013 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.000698-0.0583 uM | Newborn (0-30 days old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0066 +/- 0.0038 uM | Adult (>18 years old) | Female | Polycystic ovary syndrome (PCOS) | | details | Blood | Detected and Quantified | 0.00663 uM | Adolescent (13-18 years old) | Female | 21-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0-0.00244 uM | Adult (>18 years old) | Female | 21-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.517 uM | Infant (0-1 year old) | Both | Congenital Adrenal Hyperplasia, due to 21-Hydroxylase-Deficiency (CAH) | | details | Blood | Detected and Quantified | 0.00154-0.0174 uM | Adult (>18 years old) | Female | 21-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.00137 +/- 0.000800 uM | Newborn (0-30 days old) | Not Specified | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.000810 +/- 0.00140 uM | Children (1-13 years old) | Not Specified | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.000900-0.00420 uM | Adult (>18 years old) | Male | X-linked ichthyosis | | details | Blood | Detected and Quantified | 0.0017 uM | Adult (>18 years old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0041 uM | Adolescent (13-18 years old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00175-0.0770 uM | Newborn (0-30 days old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.000270-0.0480 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.000570 +/- 0.000200 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00103 +/- 0.00100 uM | Infant (0-1 year old) | Not Specified | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00380 +/- 0.00100 uM | Adult (>18 years old) | Male | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.00430 +/- 0.00180 uM | Adult (>18 years old) | Female | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Schizophrenia | | details | Blood | Detected and Quantified | <0.00003 uM | Adult (>18 years old) | Female | Lipoid Adrenal Hyperplasia | | details | Blood | Detected and Quantified | <0.00003 uM | Adolescent (13-18 years old) | Female | Lipoid Adrenal Hyperplasia | | details | Blood | Detected and Quantified | 0.00279-0.00454 uM | Adult (>18 years old) | Female | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.12 uM | Newborn (0-30 days old) | Female | 11-beta-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.00360-0.0227 uM | Children (1-13 years old) | Both | 11-beta-hydroxylase deficiency | | details | Blood | Detected and Quantified | 0.0090 +/- 0.0046 uM | Adult (>18 years old) | Female | Polycystic ovary syndrome (PCOS) | | details | Blood | Detected and Quantified | 0.0090 +/- 0.0065 uM | Adult (>18 years old) | Both | Cushing's syndrome | | details | Blood | Detected and Quantified | 0.0031 +/- 0.0030 uM | Adult (>18 years old) | Both | Cushing's syndrome | | details | Blood | Detected and Quantified | 0.000873 uM | Newborn (0-30 days old) | Female | Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Ovarian cancer | | details | Urine | Detected and Quantified | 0.090 +/- 0.073 umol/mmol creatinine | Adult (>18 years old) | Female | Thyroid cancer | | details | Urine | Detected and Quantified | 0.0017 +/- 0.00034 umol/mmol creatinine | Adult (>18 years old) | Both | Rheumatoid arthritis | | details | Urine | Detected and Quantified | 0.0025 +/- 0.00071 umol/mmol creatinine | Adult (>18 years old) | Both | Rheumatoid arthritis | | details | Urine | Detected and Quantified | 0.0025 +/- 0.00042 umol/mmol creatinine | Adult (>18 years old) | Both | Systemic lupus erythematosus (SLE) | | details | Urine | Detected and Quantified | 0.0047 +/- 0.0005 umol/mmol creatinine | Adult (>18 years old) | Both | Systemic lupus erythematosus (SLE) | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Polycystic ovary syndrome |
---|
- Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R: Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther. 2006 Aug;80(2):105-14. Epub 2006 Jun 30. [PubMed:16890572 ]
| Cushing's Syndrome |
---|
- Mune T, Morita H, Yasuda K, Murayama M, Yamakita N, Miura K: Elevated plasma 19-hydroxyandrostenedione levels in Cushing's disease: stimulation with ACTH and inhibition with metyrapone. Clin Endocrinol (Oxf). 1993 Mar;38(3):265-72. [PubMed:8384536 ]
| Schizophrenia |
---|
- Bicikova M, Hill M, Ripova D, Mohr P, Hampl R: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol. 2013 Jan;133:77-83. doi: 10.1016/j.jsbmb.2012.08.009. Epub 2012 Aug 24. [PubMed:22944140 ]
| Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency |
---|
- Hattori N, Ishihara T, Moridera K, Hino M, Ikekubo K, Kurahachi H: A case of late-onset congenital adrenal hyperplasia due to partial 3 beta-hydroxysteroid dehydrogenase deficiency. Endocr J. 1993 Feb;40(1):107-9. [PubMed:7951484 ]
- Lutfallah C, Wang W, Mason JI, Chang YT, Haider A, Rich B, Castro-Magana M, Copeland KC, David R, Pang S: Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 2002 Jun;87(6):2611-22. doi: 10.1210/jcem.87.6.8615. [PubMed:12050224 ]
- Guven A, Polat S: Testicular Adrenal Rest Tumor in Two Brothers with a Novel Mutation in the 3-Beta-Hydroxysteroid Dehydrogenase-2 Gene. J Clin Res Pediatr Endocrinol. 2017 Mar 1;9(1):85-90. doi: 10.4274/jcrpe.3306. Epub 2016 Jul 29. [PubMed:27476613 ]
| 11-beta-Hydroxylase deficiency |
---|
- Burren CP, Montalto J, Yong AB, Batch JA: CYP11 beta 1 (11-beta-hydroxylase) deficiency in congenital adrenal hyperplasia. J Paediatr Child Health. 1996 Oct;32(5):433-8. [PubMed:8933406 ]
| 21-Hydroxylase deficiency |
---|
- Warinner SA, Zimmerman D, Thompson GB, Grant CS: Study of three patients with congenital adrenal hyperplasia treated by bilateral adrenalectomy. World J Surg. 2000 Nov;24(11):1347-52. [PubMed:11038205 ]
- Gmyrek GA, New MI, Sosa RE, Poppas DP: Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. Pediatrics. 2002 Feb;109(2):E28. [PubMed:11826238 ]
| Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete |
---|
- Kim CJ, Lin L, Huang N, Quigley CA, AvRuskin TW, Achermann JC, Miller WL: Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab. 2008 Mar;93(3):696-702. doi: 10.1210/jc.2007-2330. Epub 2008 Jan 8. [PubMed:18182448 ]
| Congenital Adrenal Hyperplasia, due to 21-Hydroxylase-Deficiency |
---|
- Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, Longo N, Pasquali M: Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res. 2009 Aug;66(2):230-5. doi: 10.1203/PDR.0b013e3181aa3777. [PubMed:19390483 ]
| X-linked ichthyosis |
---|
- Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S, Svenstrup B: Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin Endocrinol (Oxf). 1985 Oct;23(4):385-93. [PubMed:3864567 ]
| Lipoid Congenital Adrenal Hyperplasia |
---|
- Fujieda K, Tajima T, Nakae J, Sageshima S, Tachibana K, Suwa S, Sugawara T, Strauss JF 3rd: Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest. 1997 Mar 15;99(6):1265-71. doi: 10.1172/JCI119284. [PubMed:9077535 ]
| Rheumatoid arthritis |
---|
- Straub RH, Weidler C, Demmel B, Herrmann M, Kees F, Schmidt M, Scholmerich J, Schedel J: Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2004 Aug;63(8):961-8. [PubMed:15249323 ]
| Thyroid cancer |
---|
- Kim KM, Jung BH, Lho DS, Chung WY, Paeng KJ, Chung BC: Alteration of urinary profiles of endogenous steroids and polyunsaturated fatty acids in thyroid cancer. Cancer Lett. 2003 Dec 30;202(2):173-9. [PubMed:14643447 ]
| Ovarian cancer |
---|
- Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, Nam SJ, Kim S, Bai SW, Chung BC: Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta. 2009 Feb;400(1-2):63-9. doi: 10.1016/j.cca.2008.10.014. Epub 2008 Oct 30. [PubMed:19010317 ]
|
|
---|
Associated OMIM IDs | - 184700 (Polycystic ovary syndrome)
- 181500 (Schizophrenia)
- 201810 (Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency)
- 202010 (11-beta-Hydroxylase deficiency)
- 201910 (21-Hydroxylase deficiency)
- 613743 (Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete)
- 201910 (Congenital Adrenal Hyperplasia, due to 21-Hydroxylase-Deficiency)
- 308100 (X-linked ichthyosis)
- 201710 (Lipoid Congenital Adrenal Hyperplasia)
- 180300 (Rheumatoid arthritis)
- 167000 (Ovarian cancer)
|
---|
External Links |
---|
DrugBank ID | DB01536 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB030678 |
---|
KNApSAcK ID | C00003644 |
---|
Chemspider ID | 5898 |
---|
KEGG Compound ID | C00280 |
---|
BioCyc ID | ANDROST4ENE |
---|
BiGG ID | 2210012 |
---|
Wikipedia Link | Androstenedione |
---|
METLIN ID | 2795 |
---|
PubChem Compound | 6128 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 16422 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | ANDRSTNDN |
---|
MarkerDB ID | MDB00000026 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Egorova, Olga V.; Gulevskaya, Seraphima A.; Puntus, Irina F.; Filonov, Andrey E.; Donova, Marina V. Production of androstenedione using mutants of Mycobacterium sp. Journal of Chemical Technology and Biotechnology (2002), 77(2), 141-147. |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Berkovitz GD, Guerami A, Brown TR, MacDonald PC, Migeon CJ: Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids. J Clin Invest. 1985 Jun;75(6):1763-9. [PubMed:3924954 ]
- Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH: Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006 Jun;1069:391-400. [PubMed:16855166 ]
- Schwarz S, Pohl P: Steroid hormones and steroid hormone binding globulins in cerebrospinal fluid studied in individuals with intact and with disturbed blood-cerebrospinal fluid barrier. Neuroendocrinology. 1992 Feb;55(2):174-82. [PubMed:1620285 ]
- van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R: The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002 Apr;69(4 Suppl):2-15. [PubMed:12096825 ]
- Jasuja R, Ramaraj P, Mac RP, Singh AB, Storer TW, Artaza J, Miller A, Singh R, Taylor WE, Lee ML, Davidson T, Sinha-Hikim I, Gonzalez-Cadavid N, Bhasin S: Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men. J Clin Endocrinol Metab. 2005 Feb;90(2):855-63. Epub 2004 Nov 2. [PubMed:15522925 ]
- Egloff M, Savoure N, Tardivel-Lacombe J, Massart C, Nicol M, Degrelle H: Influence of sex hormone binding globulin and serum albumin on the conversion of androstenedione to testosterone by human erythrocytes. Acta Endocrinol (Copenh). 1981 Jan;96(1):136-40. [PubMed:7192922 ]
- Zarrilli S, Lombardi G, Paesano L, Di Somma C, Colao A, Mirone V, De Rosa M: Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy. Andrologia. 2000 May;32(3):147-54. [PubMed:10863969 ]
- Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanen A, Knekt P: Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999 Jul 15;86(2):312-5. [PubMed:10421267 ]
- Schlaghecke R, Kley HK, Kruskemper HL: The measurement of 4-androstene-3, 11, 17-trione (11-oxo-androstenedione) by radioimmunoassay in human plasma. Steroids. 1984 Jul;44(1):23-33. [PubMed:6100340 ]
- King DS, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL, Parsons KA: Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA. 1999 Jun 2;281(21):2020-8. [PubMed:10359391 ]
- Johansson A, Henriksson A, Olofsson BO, Olsson T: Adrenal steroid dysregulation in dystrophia myotonica. J Intern Med. 1999 Apr;245(4):345-51. [PubMed:10356596 ]
- Atkinson G, Campbell DJ, Cawood ML, Oakey RE: Steroids in human intrauterine fluids of early pregnancy. Clin Endocrinol (Oxf). 1996 Apr;44(4):435-40. [PubMed:8706310 ]
- Zarrilli S, Paesano L, Mirone V, Finelli L, De Rosa M: [Evaluation of seminal and hormonal parameters in idiopathic varicocele before and after surgical intervention]. Chir Ital. 1998 Mar-Aug;50(2-4):21-8. [PubMed:11762080 ]
- Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R: Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther. 2006 Aug;80(2):105-14. Epub 2006 Jun 30. [PubMed:16890572 ]
- Thomson S, Wallace AM, Cook B: A 125I-radioimmunoassay for measuring androstenedione in serum and in blood-spot samples from neonates. Clin Chem. 1989 Aug;35(8):1706-12. [PubMed:2758640 ]
- Riikonen RS: How do cryptogenic and symptomatic infantile spasms differ? Review of biochemical studies in Finnish patients. J Child Neurol. 1996 Sep;11(5):383-8. [PubMed:8877606 ]
- Azurmendi A, Braza F, Sorozabal A, Garcia A, Braza P, Carreras MR, Munoz JM, Cardas J, Sanchez-Martin JR: Cognitive abilities, androgen levels, and body mass index in 5-year-old children. Horm Behav. 2005 Aug;48(2):187-95. [PubMed:15878571 ]
- Schairer C, Hill D, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN, Sherman ME: Serum concentrations of estrogens, sex hormone binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1660-5. [PubMed:16030098 ]
- Feldman PS, Kovacs K, Horvath E, Adelson GL: Malignant Leydig cell tumor: clinical, histologic and electron microscopic features. Cancer. 1982 Feb 15;49(4):714-21. [PubMed:7055782 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
---|